192 related articles for article (PubMed ID: 33131745)
1. Targeting CXCL12-CXCR4 Signaling Enhances Immune Checkpoint Blockade Therapy Against Triple Negative Breast Cancer.
Lu G; Qiu Y; Su X
Eur J Pharm Sci; 2021 Feb; 157():105606. PubMed ID: 33131745
[TBL] [Abstract][Full Text] [Related]
2. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
3. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics.
Wei R; Li J; Lin W; Pang X; Yang H; Lai S; Wei X; Jiang X; Yuan Y; Yang R
Acta Biomater; 2024 Mar; 177():414-430. PubMed ID: 38360292
[TBL] [Abstract][Full Text] [Related]
5. A hierarchical tumor-targeting strategy for eliciting potent antitumor immunity against triple negative breast cancer.
Lin M; Cai Y; Chen G; Zhong H; Li B; Li T; Xiao Z; Shuai X
Biomaterials; 2023 May; 296():122067. PubMed ID: 36854221
[TBL] [Abstract][Full Text] [Related]
6. Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer.
Sceneay J; Goreczny GJ; Wilson K; Morrow S; DeCristo MJ; Ubellacker JM; Qin Y; Laszewski T; Stover DG; Barrera V; Hutchinson JN; Freedman RA; Mittendorf EA; McAllister SS
Cancer Discov; 2019 Sep; 9(9):1208-1227. PubMed ID: 31217296
[TBL] [Abstract][Full Text] [Related]
7. Targeting CXCR4/CXCL12 axis via [
Bao G; Wang Z; Liu L; Zhang B; Song S; Wang D; Cheng S; Moon ES; Roesch F; Zhao J; Yu B; Zhu X
Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38587644
[TBL] [Abstract][Full Text] [Related]
8. Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer.
Wu W; Xu M; Qiao B; Huang T; Guo H; Zhang N; Zhou L; Li M; Tan Y; Zhang M; Xie X; Shuai X; Zhang C
Acta Biomater; 2023 Mar; 158():547-559. PubMed ID: 36539109
[TBL] [Abstract][Full Text] [Related]
9. Liposomal ATM siRNA delivery for enhancing triple-negaitive breast cancer immune checkpoint blockade therapy.
Yu D; Wang H; Liu H; Xu R
J Biomater Appl; 2023 May; 37(10):1835-1846. PubMed ID: 37016537
[TBL] [Abstract][Full Text] [Related]
10. CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation.
Zhou KX; Xie LH; Peng X; Guo QM; Wu QY; Wang WH; Zhang GL; Wu JF; Zhang GJ; Du CW
Cancer Lett; 2018 Apr; 418():196-203. PubMed ID: 29317253
[TBL] [Abstract][Full Text] [Related]
11. Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
Alghamri MS; Banerjee K; Mujeeb AA; Mauser A; Taher A; Thalla R; McClellan BL; Varela ML; Stamatovic SM; Martinez-Revollar G; Andjelkovic AV; Gregory JV; Kadiyala P; Calinescu A; Jiménez JA; Apfelbaum AA; Lawlor ER; Carney S; Comba A; Faisal SM; Barissi M; Edwards MB; Appelman H; Sun Y; Gan J; Ackermann R; Schwendeman A; Candolfi M; Olin MR; Lahann J; Lowenstein PR; Castro MG
ACS Nano; 2022 Jun; 16(6):8729-8750. PubMed ID: 35616289
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
13. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer.
Chen IX; Chauhan VP; Posada J; Ng MR; Wu MW; Adstamongkonkul P; Huang P; Lindeman N; Langer R; Jain RK
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4558-4566. PubMed ID: 30700545
[TBL] [Abstract][Full Text] [Related]
14. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
Gao M; Wang T; Ji L; Bai S; Tian L; Song H
Front Immunol; 2020; 11():366. PubMed ID: 32194569
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response.
Biasci D; Smoragiewicz M; Connell CM; Wang Z; Gao Y; Thaventhiran JED; Basu B; Magiera L; Johnson TI; Bax L; Gopinathan A; Isherwood C; Gallagher FA; Pawula M; Hudecova I; Gale D; Rosenfeld N; Barmpounakis P; Popa EC; Brais R; Godfrey E; Mir F; Richards FM; Fearon DT; Janowitz T; Jodrell DI
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28960-28970. PubMed ID: 33127761
[TBL] [Abstract][Full Text] [Related]
16. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
17. CXCR4 expression is elevated in TNBC patient derived samples and Z-guggulsterone abrogates tumor progression by targeting CXCL12/CXCR4 signaling axis in preclinical breast cancer model.
Gupta N; Mohan CD; Shanmugam MK; Jung YY; Chinnathambi A; Alharbi SA; Ashrafizadeh M; Mahale M; Bender A; Kumar AP; Putti TC; Rangappa KS; Zhang X; Ahn KS; Sethi G
Environ Res; 2023 Sep; 232():116335. PubMed ID: 37290620
[TBL] [Abstract][Full Text] [Related]
18. ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer.
Wang G; Romero Y; Thevarajan I; Zolkiewska A
Oncoimmunology; 2023; 12(1):2158006. PubMed ID: 36545255
[TBL] [Abstract][Full Text] [Related]
19. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
Benedicto A; Romayor I; Arteta B
Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
